Medical specialization dealing with gynecological diseases and obstetrics.


Early detection of preeclampsia

Preeclampsia is a hypertensive disease during pregnancy, which is mainly characterized by high blood pressure and proteinuria (increased protein loss in the urine). In Western Europe, preeclampsia develops in 5-7% of all pregnancies, around 50,000 women worldwide die each year from preeclampsia and its consequences. An early biomarker could be of decisive help in diagnosing the disease in good time and significantly reducing the risks for mother and child.

New opportunities

DIAGENICS has developed a method that makes it possible to diagnose preeclampsia at an early stage using a biomarker: glycogen phosphorylase BB (GPBB). This enzyme is specific for the heart, brain and placenta and is released into the bloodstream in the early stages of ischemia - much earlier than all necrosis markers.


Preeclampsia affects 5-8% pregnant women
(7 times more in the third world)

135 million births worldwide

DIAGENICS has patent-protected antibodies to this enzyme and has already developed a new product line for early diagnosis of preeclampsia: DIANEONATAL.®Current and future studies will further expand our expertise in the field of preeclampsia diagnosis.

Our Products